Constellation Pharmaceuticals and the University of Pittsburgh School of Medicine Receive Cystic Fibrosis Foundation Research Grant
CAMBRIDGE, Mass. – October 10, 2013 – Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the field of epigenetics, today announced that it has been awarded a research grant in collaboration with the University of Pittsburgh School of Medicine from the Cystic Fibrosis Foundation to explore the potential use of BET bromodomain inhibitors for the control of inflammation in cystic fibrosis.
“This research grant will facilitate the study of the epigenetic control of inflammation, an area of active research at Constellation, in the context of a disease for which the treatment options are very limited,” commented Jose Lora, Ph.D., executive director of preclinical sciences at Constellation.
Through the grant, Constellation Pharmaceuticals will collaborate with the laboratory of Jay Kolls, M.D., director, Richard King Mellon Foundation Institute for Pediatric Research at Children’s Hospital of Pittsburgh of UPMC, and professor of pediatrics and immunology at University of Pittsburgh School of Medicine. Dr. Kolls’ laboratory is a pioneer in the mechanistic understanding of cystic fibrosis, and has made fundamental contributions to the concept of inflammation as a key component of the pathophysiology of this disease.
The research supported by this grant will test the preclinical efficacy of novel anti-inflammatory compounds to reduce potential lung-damaging inflammation in people with cystic fibrosis.
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis and funds more cystic fibrosis research than any other organization.
About Constellation Pharmaceuticals
Constellation Pharmaceuticals leverages insights from the rapidly expanding field of epigenetics to discover and develop small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The company’s innovative product discovery engine targets both enzymes that modify the dynamic structure of chromatin (writers and erasers) and other proteins that interact with chromatin (readers) to control gene expression. Restoration of normal gene expression through chromatin modulation by highly selective and specific inhibitors promises to be a powerful avenue for the development of important new medicines against a broad range of diseases. For more information, please visit the company's website at constpharma.wpengine.com.
About the University of Pittsburgh School of Medicine
As one of the nation’s leading academic centers for biomedical research, the University of Pittsburgh School of Medicine integrates advanced technology with basic science across a broad range of disciplines in a continuous quest to harness the power of new knowledge and improve the human condition. Driven mainly by the School of Medicine and its affiliates, Pitt has ranked among the top 10 recipients of funding from the National Institutes of Health since 1998. In rankings recently released by the National Science Foundation, Pitt ranked fifth among all American universities in total federal science and engineering research and development support.
Likewise, the School of Medicine is equally committed to advancing the quality and strength of its medical and graduate education programs, for which it is recognized as an innovative leader, and to training highly skilled, compassionate clinicians and creative scientists well-equipped to engage in world-class research. The School of Medicine is the academic partner of UPMC, which has collaborated with the University to raise the standard of medical excellence in Pittsburgh and to position health care as a driving force behind the region’s economy. For more information about the School of Medicine, see www.medschool.pitt.edu.
About the Antonio J. and Janet Palumbo Cystic Fibrosis Center
The Antonio J. and Janet Palumbo Cystic Fibrosis Center (CF Center) at Children's Hospital of Pittsburgh of UPMC is dedicated to providing state-of-the-art care to patients and families with cystic fibrosis, education for health care professionals, and conducting clinical and basic research in cystic fibrosis. The program is accredited by the Cystic Fibrosis Foundation for clinical care and research.
About the Cystic Fibrosis Foundation
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more cystic fibrosis research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The Cystic Fibrosis Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.
Pure Communications, Inc.